Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$56.66 USD
-2.41 (-4.08%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $55.92 -0.74 (-1.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRBP 56.66 -2.41(-4.08%)
Will CRBP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging HealthEquity (HQY) This Year?
Other News for CRBP
Marijuana Stock Movers For August 2, 2024
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing (CORRECTED)
Affirm, Sprouts Farmers upgraded: Wall Street's top analyst calls
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
Wedbush starts Corbus with Outperform on cancer and obesity potential